Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
free free
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll The aggresome pathway as a target for therapy in hematologic malignancies Simms-Waldrip T; Rodriguez-Gonzalez A; Lin T; Ikeda AK; Fu C; Sakamoto KMMol Genet Metab 2008[Jul]; 94 (3): 283-6Misfolded or unfolded proteins are often refolded with the help of chaperones or degraded by the 26S proteasome. An alternative fate of these proteins is the aggresome pathway. The microtubule-organizing center (MTOC) transports unfolded proteins to lysosomes and are degraded through autophagy. Histone deacetylase 6 (HDAC6) deacetylates alpha-tubulin, which is thought to be a component of the MTOC. Recently, two small molecule inhibitors of the aggresome pathway and HDAC6 have been described. One inhibitor, tubacin, prevents deacetylation of alpha-tubulin and produces accumulation of polyubiquitinated proteins and apoptosis. Tubacin acts synergistically with the proteasome inhibitor, bortezomib, to induce cytotoxicity in one type of hematologic malignancy, multiple myeloma. The other, LBH589, is a pan HDAC inhibitor and hydroxamic acid derivative that induces apoptosis of multiple myeloma cells resistant to conventional therapies. In this review, we summarize recent reports on targeting the aggresome pathway and HDAC6 in hematologic malignancies.|*Drug Delivery Systems/methods[MESH]|*Protein Folding[MESH]|Endoplasmic Reticulum/metabolism/*physiology[MESH]|Enzyme Inhibitors/pharmacology/therapeutic use[MESH]|Hematologic Neoplasms/*drug therapy[MESH]|Histone Deacetylase 6[MESH]|Histone Deacetylase Inhibitors[MESH]|Histone Deacetylases/physiology[MESH]|Humans[MESH]|Models, Biological[MESH]|Molecular Chaperones/physiology[MESH]|Proteasome Endopeptidase Complex/physiology[MESH]|Protein Processing, Post-Translational/*physiology[MESH]|Signal Transduction/physiology[MESH]|Ubiquitination/physiology[MESH] |